Tillotts Pharma AG
Patent owner in reexamination·2 ex parte reexams
Tillotts Pharma AG's patents have been the subject of 2 USPTO ex parte reexaminations. Its patents are most often challenged by David W. Clough, Ph.D.. ExamPat indexes the full prosecution record for each proceeding, including office-action grounds, certificate outcomes, and downstream PTAB and Federal Circuit decisions.
Filings by year
Top requesters
Outcome track record
How reexams of this owner's patents resolve: claims confirmed, amended, mixed, or fully canceled.
- Certificate outcome split across every bucket
- Claim-survival rate
Defense metrics
Claim-survival rate, average pendency, and the open/closed split across every reexam of this owner's patents.
- Survival rate of closed proceedings
- Average pendency in months
Challengers & examiners
Which requesters most often challenge this owner's patents, and which examiners decide them.
- Top requesters
- Most frequent examiners
Recent reexaminations (2)
| Control # | Filed | Patent | Title | Requester | Status |
|---|---|---|---|---|---|
| 90/012,827 | Apr 3, 2013 | 5,792,795 | Treatment of Inflammatory Bowel Disease Using Oral Dosage Forms of Omega-3 Polyunsaturated Acids | — | Closed |
| 90/012,224 | Mar 30, 2012 | 5,948,818 | TREATMENT OF INFLAMMATORY BOWEL DISEASE USING ORAL DOSAGE FORMS OF OMEGA-3 POLYUNSATURATED ACIDS | David W. Clough, Ph.D. | Closed |
See the full reexam picture for Tillotts Pharma AG
Certificate outcomes, pendency, and the parties and examiners behind these cases. Free to sign up.